Drug Profile

Research programme: COVID-19 neutralising antibodies - Aegis Life

Alternative Names: COVID-19 nAbs - Aegis Life

Latest Information Update: 28 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aegis Life
Class Antibodies; Antivirals; Nucleic acids
Mechanism of Action DNA modulators; RNA modulators; Virus internalisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Dec 2021 COVID-19 neutralising antibodies is available for licensing as of 28 Dec 2021. https://aegis.life/
01 Dec 2021 Preclinical trials in COVID-2019 infections in USA (Parenteral) before December 2021 (Aegis Life pipeline, December 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com